Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection

AIDS

Volumn 12, Issue 13, 1998, Pages 1591-1600

  Carotenuto, Patrizia ^a   Looij, Dennis ^a   Keldermans, Lian ^a   De Wolf, Frank ^a   Goudsmit, Jaap ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

HIV 1 primary isolates; Human; Neutralizing antibodies; Progression markers

Indexed keywords

CD4 ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS RNA;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE;

CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; KINETICS; LONGITUDINAL STUDIES; RNA, VIRAL; T-LYMPHOCYTES; VIRAL LOAD;

EID: 0032505017     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199813000-00005     Document Type: Article

References (36)

1. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune response with the initial control of viremia in primary HIV-1 syndrome. J Virol 1994, 68:4650-4655.
2. Pellegrin I, Legrand E, Neau D, et al.: Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr 1996, 11:438-447.
3. Robert-Guroff M, Brown M, Callo RC: HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1986, 316:72-74.
4. Hogervorst E, Jurrians F, de Wolf F, et al.: Predictors for non-and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995, 171:811-821.
5. Zang Y, Fracasso C, Fiore JR, et al.: Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1 infected long-term nonprogressors. J Infect Dis 1997, 176:1180-1187.
6. Klein MR, Miedema F: Long-term survivors of HIV-1 infection. Trends Microbiol 1995, 3:586-391.
7. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996, 382:722-725.
8. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
9. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
10. Learmont J, Cook L, Dunckley H, Sullivan JS: Update on long-term symptomless HIV type 1 infection in recipients of blood products from a single donor [letter]. AIDS Res Hum Retroviruses 1995, 11:1.
11. Kirchhoff F, Grenough TC, Brettler DB, Sullivan JL, Desrosiers RC: Absence of intact nef sequences in a long-term survivor with non progressive HIV-1 infection. N Engl J Med 1995, 332:228-232.
12. Klein MR, van Baalen CA, Holwerda AM, et al.: Kinetics of gag specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long term asymptomatics. J Exp Med 1995, 181:1365-1372.
13. Rinaldo C, Huang XL, Fan Z, et al.: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J Virol 1995, 69:5838-5842.
14. Cao Y, Qing E, Zhang L, Safrit J, Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332:201-208.
15. Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
16. Weiss RA, Clapham PR, Cheingsong-Popov R, et al.: Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS risk-patients. Nature 1985, 316:69-72.
17. Daar ES, Li XL, Moudgil T, Ho DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990, 87:6574-6578.
18. Moore JP, Cao Y, Qing E, et al.: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995, 69:101-109.
19. Moore JP, Ho DD: HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 1995, 9 (suppl A):S1-S19.
20. Montefiori DC, Pantaleo G, Fink EM, et al.: Neutralizing and infection enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996, 173:60-67.
21. Harrer T, Harrer E, Kalams SA, et al.: Strong cytotoxic T cell and weak neutralising antibody responses in a subset of persons with stable non progressing HIV type 1 infection. AIDS Res Hum Retroviruses 12:585-592.
22. Pilgrim AK, Pantaleo G, Cohen OJ, et al.: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis1997, 176:924-932.
23. Cornelissen M, Hogervorst E, Zorgdrager F, Hartman S, Goudsmit J: Maintenance of syncytium inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp120 V2 domain without fixed positions, elongation or relocated N-linked glycosylation sites. AIDS Res Hum Retroviruses 1995, 11:1169-1175.
24. Berber EA, Doms RW, Fenyo EM, et al.: A new classification for HIV-1 [correspondence]. Nature 1998, 391:240.
25. Van Griensven GJP, Tielman RAP, Goudsmit J, et al.: Risk factors and prevalence of HIV antibodies in homosexual men in The Netherlands. Am J Epidemiol 1987, 125:1048-1057.
26. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993, 41:1-19.
27. Schellekens PTA, Roos MTL, de Wolf F, Lange JMA, Miedema F: Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for AIDS in HIV-1 infected men. J Clin Immunol 1990, 10:121-127.
28. Jurriaans S, van Gemen B, Wevering GJ, et al.: The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994, 204:223-233.
29. Carotenuto P, Keldermans L, Bakkus M, et al.: Antibody mediated inhibition of HIV-1 primary isolate replication and plasma viral load in long-term survivors. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15 (suppl 1):S59-S63.
30. Moore JP: Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to sCD4 by ELISA: HIV-2 has a 25-fold lower affinity than HIV-1 for sCD4. AIDS 1990, 3:297-305.
31. Bongertz V, Costa CI, Santos VGV, et al.: Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies. AIDS 1997, 11:969-975.
32. Moog C, Fleury JAF, Pellegrin A, Kim A, Aubertin AM: Autologous and heterologous neutralizing antibodies following initial seroconversion in human immunodeficiency virus type 1 infected individuals. J Virol 1997, 71:3734-3741.
33. Albert J, Abrahamson B, Nagy K, et al.: Rapid development of isolate specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990, 4:107-112.
34. Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen I, Niesen OJ: Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape-virus neutralizing antibodies. J Acquir Immune Defic Syndr 1992, 5:303-307.
35. Tsang ML, Evans LA, McQueen P, et al.: Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis 1994, 170:1141-1147.
36. Strathdee SA, Frank JW, McLaughlin J, et al.: Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS. J Infect Dis 1995, 172:1375-1379.